8th January 2019

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir / Madam,

Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we give below, the schedule of analyst / institutional investor meetings with the Company:

<table>
<thead>
<tr>
<th>Date</th>
<th>Fund / Investor Name</th>
<th>Venue</th>
<th>Type of Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>08-Jan-19</td>
<td>37th Annual JP Morgan Healthcare Conference</td>
<td>San Francisco</td>
<td>In person</td>
</tr>
</tbody>
</table>

The presentation that will be made at the 37th Annual J.P. Morgan Healthcare Conference is enclosed and is also available on our website at the following URL: https://www.cipla.com/en/investor-information/intimation-to-stock-exchanges.html

Thank you,

Yours faithfully,

For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Juzer Masta
Global generic enterprise moving up the value chain to Specialty
Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

This document and its contents is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes “g” and “generic" used interchangeably indicate the generic versions of the named brand drugs.
Established in 1935, Cipla is a pioneer in the Indian pharmaceutical industry.

Cipla started as a small Indian enterprise, committed to the nation’s quest for self-sufficiency – today it has transformed into a world-class global pharmaceutical player.

YEARS OF CARING 83

$2.4B Revenues
18.6% EBITDA

80+ Markets
23,000+ Employees

44 state of art Manufacturing facilities
50+ Dosage forms

Note: Data as per FY18 numbers
At Cipla, we are well positioned to …

1. **Strengthen leadership position** in branded markets of India, South Africa and EMs

2. Establish our **footprint in new growth markets** - Brazil and China

3. Continue to deliver on **complex generic assets in US** *(including key Respiratory assets)*

4. Accelerate **innovation-led journey** with key Specialty investments in US

5. Continue our track record of a **high quality global pharmaceutical manufacturer**

6. Remain core to our purpose of ‘**Caring for Life**’ and putting **patients’ interest** first
Cipla has substantially strengthened its financial profile and Governance

- Significant expansion in EBITDA margins, cash flow and balance sheet health improvement

18.6% EBITDA Margin (FY18)

+150bps Improvement in RoIC (FY18)

0.15 Net Debt/ Equity (Sept’18)

Accelerated impact: ~$100 M savings identified from 1000+ ideas in 18 months; 60% ideas already implemented and accruing

Institutionalized cost culture: 250+ people driving cost initiatives on a daily basis across functions; setup of dedicated central & functional Continuous Improvement (CI) teams to drive the program

Continue momentum on ambitious cost optimization programs in order to boost margin profile and future growth

Golden Peacock Award for Excellence in Corporate Governance – 2018
We have enhanced our global footprint with...

- strong portfolio and execution capabilities across our **branded market franchises** in India, South Africa and key emerging markets (including Europe)

### EM and Europe

- In-licensed Biosimilars franchise in EMs
- Respiratory launches in Europe
- Targeting new growth markets in Brazil and China

### India

- Therapy focused Medical-Representatives structure
- Specialty molecules – partnerships with Big Pharma
- Respiratory – Patient outreach ‘Berok Zindagi’ Campaign

### South Africa

- Teva partnership – Biosimilar launches
- OTC Expansion – acquisition of Mirren
- Regional strategy for Africa (SAGA Launch)
Our journey to build an innovation led business is getting accelerated

- Enhanced play in the US generics market with key complex assets
- Significant focus and investments in the US Specialty business

### US Generics Business Growth

<table>
<thead>
<tr>
<th>5x Organic DTM: From $40M in FY17 to ~$200M* US business</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key Complex Assets Approved</td>
</tr>
<tr>
<td>- Diclofenac, Metoprolol, Isoproterenol, Testosterone injection</td>
</tr>
<tr>
<td>On track to file 20+ ANDAs in FY19</td>
</tr>
<tr>
<td>gAdvair Trials initiated</td>
</tr>
</tbody>
</table>

### Specialty Business Investments

**Cipla’s first large specialty transaction** – major milestone towards our US hospital specialty strategy - USD 215 mn# investment

- $35mn to be invested as first tranche for 33.3% equity stake; second tranche contingent on key label conditions

**Multiple additional institutional assets under late-stage evaluation**

*Q4 FY19 estimated sales annualized ; # Excluding CVRs
India: Continues to be a key component of Cipla’s growth story, providing a strong base for global expansion

**Therapy-wise revenue breakup**

- **FY18**
  - Respiratory: 31%
  - Anti-infectives: 21%
  - Cardio-Metabolic: 13%
  - Gastro-Intestinal: 6%
  - Antivirals: 5%
  - Urology: 5%
  - CNS: 4%
  - Others: 15%

**Continued Growth across our Portfolio**

- 4 therapies ranked amongst top 3 – contributing to 62% of Cipla's revenue share

**25 of the top 30 brands outpacing market by 2-3%**

**Consumer access programs**

- Targeting improved outcomes through a combination of pharma & digital therapeutics
- Ecosystem for affordable treatment for oncology patients
- Launched patient management solutions for physicians

**Diversifying and expanding business lines through in-licensing**

**Oncology**
- Tocilizumab (Actemra®)
- Bevacizumab (Syndyna®)
- Trastuzumab (Biceltis®)
- Rituximab (Ikgdar®)

**Diabetes**
- Canagliflozin (Prominad®)
- Mannkind
- Inhaled Insulin (Afrezza®)
- Janssen
- Novartis
- Vildagliptin (Vysov®)
- Eli Lilly
- Insulin Giargine (Basaglar®)
- Roche

**Cardiology**
- Sacubitril + Valsartan (Azmarda®)
- Mannkind
- Novartis

---

1. As per Cipla’s internal analysis | 2. IQVIA (IMS) MAT Nov’18 | 3. IQVIA (IMS) MAT Sept’18; IPM: Indian Pharmaceuticals Market

The trademarks contained herein are the registered trademarks of the respective companies in India.
We have started our ‘Beyond The Pill’ journey Reimagining our Future, Ecosystem and Roles in our core markets

Expanding across the value chain in home markets

- **Awareness**
  - #BerokZindagi Inhaler awareness campaign
  - Breathefree campaign for asthma/COPD awareness

- **Diagnosis**
  - Low cost Spirometers
  - Breathe-o-meters
  - Peak flow meters

- **Treatment**
  - Smart inhalers
  - Financing options
  - Digital Stethoscope

- **Compliance**
  - Chronic Disease Management through digital therapeutic
  - Integrated HC Ecosystem
  - Clinic management solutions

<table>
<thead>
<tr>
<th>Patient</th>
<th>✓</th>
<th>✓</th>
<th>✓</th>
<th>✓</th>
<th>✓</th>
<th>✓</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescriber</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>
1. SAGA*: 3rd largest in private market in South Africa; Growing through partnerships and expansion of OTC and biosimilar portfolio

**Cipla South Africa**

| 3rd       | Largest Private Market Player | 3x Market Growth @ 11.5%¹ | 6.5% Market Share |

**Continued Portfolio Expansion in the Prescription Business**

- Tenofovir Lamivudine Dolutegravir (TLD)
- Tenofovir Lamivudine Dolutegravir Actuated Inhaler launch
- First Biosimilar Launch in SA
- TEVA Partnership

**OTC: Key driver for growth**

- In the categories where we play, 1 out of every 4 patients leave a pharmacy with a Cipla OTC product²

**Strengthened OTC in SA with Mirren acquisition**

* SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access business | Note: Cipla SA data is considered inclusive of Mirren.

1. IQVIA (IMS) MAT Nov’18. | 2. IQVIA (IMS) MAT Sep’18
SAGA*: Expanding patient access in Sub-Saharan Africa by making ‘In Africa for Africa’

Cipla QCIL in Uganda

- Government of Uganda guaranteed offtake extended to FY29
- Secured offtake with Government of Zambia for supply of ARVs, ACTs and hepatitis treatments

New partnership agreements signed for
Expanding access to affordable cancer treatment in Africa

Only supplier of
- Artesunate Rectocaps (anti-malarials)
- Lopinavir + Ritonavir pellets (HIV/AIDS)

WHO approval – Q-TIB, a Cipla world-first FDC single-tablet aimed at reducing mortality from comorbidity burden among HIV patients

EM EU: Exhibited entrepreneurial spirit, managed market volatility, dialled up inorganic quotient

Diversified risk profile across 50+ markets by limiting DTM to 13 markets

Expansion of respiratory portfolio across various European markets

Significant investments towards improving Awareness, Detection & Adherence in Emerging markets via strong consumer access programs such as #ScoreUp#SaveYourLungs#CommittedToZero

Expansion through organic investments and inorganic partnerships

Cipla Brazil to be the next innovation engine in the country on Oncology

Strong Biosimilars pipeline through partnerships

Trastuzumab
select countries in APAC, MENA and LATAM

Bevacizumab
select countries in APAC, MENA and LATAM

Rituximab
select countries in North Africa

New mfg plant in Morocco
Inhalers plant in North Africa

Gearing up for the game in China via partnerships in Respi
US: With strong development pipeline and flagging off new Institutional business

**Growth Portfolio: Institutional CNS, Respiratory, Oncology**

US Contribution* in overall revenues

<table>
<thead>
<tr>
<th>Year</th>
<th>FY '19 Est</th>
<th>FY '20</th>
<th>FY '21</th>
<th>FY '22</th>
<th>FY '23</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>19%</td>
<td>30%</td>
<td>30%</td>
<td>30%</td>
<td>~30%</td>
</tr>
</tbody>
</table>

**Focus on Specialty (Respiratory & CNS) & Institutional**

- Acquired Phase 3 pain-management asset IV Tramadol
- Tizanidine transdermal patch under-development
- Active exploration of acquisition / in-licensing

**Filings: In-line with guidance**

- Filings: In-line with Guidance (20+ in FY19 on-track)
- gAdvair: Phase III Started

**Organic growth drivers**

- Organic DTM: $40M to $200#M US business
- 3 Big Launches: Diclofenac, Budesonide, Isoproterenol
- Key Approvals: Low competition products: Isoproterenol, Testosterone injection

* FY ‘19 onwards, for illustrative purposes only - not to scale; # *Q4 FY19 estimated sales annualized
US: Filings for under-development products in the US will bolster future growth

Split of top 30 projects

- **Therapy**: Respiratory 6, Anti-HIV 4, Anti-infectives 3
- **Others**: Oncology 14, Others 4

Dosage form

- **Orals Solids**: 10
- **Injectables**: 9
- **Topicals**: 4
- **Inhalation**: 5

Complexity

- **Simple**: 5
- **Medium**: 13
- **Complex**: 12

Brand sales value

- > $500mn: 13
- $100-500mn: 13
- < $100mn: 4
- Others: 4

18 Para IV Filings primarily in Respiratory, Anti-HIV and Oncology

14+ limited competition products

Respiratory, Anti-HIV and Oncology pipeline has a brand market size of ~ US$ 20bn

Of the 100+ development projects, top 30 have market size of > US$ 25bn

1. Competition stats are as per Cipla’s analysis
### US: Focusing on limited competition opportunities through tech and product centricity

**Pipeline of 30+ Products with $23B market size leveraging our Scientific Capabilities**

<table>
<thead>
<tr>
<th>Innovative Technology Platforms</th>
<th>Inhalation technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal Development</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Innovative Technology Platforms</th>
<th>Suspension based liquids</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Liposome/ Nano injections</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Innovative Technology Platforms</th>
<th>Peptide based Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**16+ Products with $32B market size leveraging External Partnerships**

<table>
<thead>
<tr>
<th>Innovative Technology Platforms</th>
<th>Microspheres Depot</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Insulin-analogues / Biosimilars</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Innovative Technology Platforms</th>
<th>Complex API's</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Others</td>
</tr>
</tbody>
</table>
Cipla has signed the agreement to acquire US-based Avenue Therapeutics

We are on our journey to realize our long term aspiration of becoming a Global Specialty Pharma

Cipla’s first large specialty transaction – major milestone towards our US hospital specialty strategy – USD 215mn investment

$35mn to be invested as first tranche for 33.3% equity stake; second tranche contingent on key label conditions

IV TRAMADOL

- Addresses unmet need in post-op pain management
- Expected to be the first Schedule-4 IV drug in US
- Dual action mechanism with low risk of addiction

1. Excluding Contingent Value Rights based on performance
Cipla continues to focus on excellence in quality and compliance across manufacturing locations

Finished formulations
- 30+ formulations facilities
- 50+ dosage forms
- 1500+ products

APIs
- 5+ API facilities
- 1000+ tons capacity

74\(^1\) successful audits conducted by global regulatory bodies across our facilities\(^2\)

Increased automation to further strengthen quality and control processes

2. Select sites also have approvals from Denmark, France, Uganda, Singapore, Latvia, Tanzania, Kenya, Russia and various other countries

22 successful audits in 2018 alone including 5 USFDA audits
Overall, we are on the path to make our business more sustainable

We aspire to go "Beyond the pill" and offer solutions to our patients, in our quest to be a "Global Specialty Company"
To recap, Cipla is well positioned to …

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>Strengthen leadership position in branded markets of India &amp; South Africa</strong></td>
</tr>
<tr>
<td>2.</td>
<td>Establish our <strong>footprint in new growth markets - Brazil and China</strong></td>
</tr>
<tr>
<td>3.</td>
<td>Continue to deliver on <strong>complex generic assets in US</strong> <em>(including key Respiratory assets)</em></td>
</tr>
<tr>
<td>4.</td>
<td>Accelerate <strong>innovation-led journey</strong> with key Specialty investments in US</td>
</tr>
<tr>
<td>5.</td>
<td>Continue our track record of a <strong>high quality global pharmaceutical manufacturer</strong></td>
</tr>
<tr>
<td>6.</td>
<td>Remain core to our purpose of ‘<strong>Caring for Life</strong>’ and putting patients’ interest first</td>
</tr>
</tbody>
</table>
Thank You

Contact Details

Registered Office:
Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

For any general queries, Reach us at:
Naveen.Bansal1@cipla.com
Investor.Relations@cipla.com

For more information please visit
www.cipla.com